Results 31 to 40 of about 3,716,801 (336)
Farnesyltransferase inhibitors
Seminars in Oncology, 2001 The targeting of molecular abnormalities in neoplasms may provide an opportunity to improve the selectivity of cancer therapy. Ras mutations are a common genetic event in human cancers. Other genetic changes in tumors can signal through ras-dependent pathways as well.
Hahn, S, Bernhard, E, Mckenna, W
openaire +3 more sources
Química Nova, 2009 The development and characterization of bioreactors or IMER (immobilized enzyme reactors) as research tools are important in the scope of medicinal chemistry and constitute an alternative for the rational development of drugs.
Carmen Lúcia Cardoso +2 more
doaj +1 more source
The potential role and application of PARP inhibitors in cancer treatment [PDF]
, 2009 Background: Since many anti-cancer agents act by inflicting DNA damage on tumour cells, there is increasing interest in the use of inhibitors of DNA repair to increase the cytotoxicity of these agents.
Chalmers, Anthony J
core +2 more sources
The Development of CK2 Inhibitors: From Traditional Pharmacology to in Silico Rational Drug Design
Pharmaceuticals, 2017 Casein kinase II (CK2) is an ubiquitous and pleiotropic serine/threonine protein kinase able to phosphorylate hundreds of substrates. Being implicated in several human diseases, from neurodegeneration to cancer, the biological roles of CK2 have been ...
Giorgio Cozza
doaj +1 more source
Comparison of nitrification inhibitors to restrict nitrate leaching in a maize crop irrigated under mediterranean conditions [PDF]
, 2010 The aim of this paper was to compare dicyandiamide (DCD) and 3,4 dimethylpyrazole phosphate (DMPP) as inhibitors of ammonium oxidation and nitrate leaching after applying fertilizer to a maize (Zea mays L.) crop grown under Mediterranean conditions.
Arauzo, M. +4 more
core +3 more sources
The Oncologist, 2010 AbstractInhibitors of mammalian target of rapamycin (mTOR) have been approved for the treatment of renal cell carcinoma and appear to have a role in the treatment of other malignancies. The primary objective of this drug review is to provide pharmacokinetic and dynamic properties of the commonly used drugs everolimus and temsirolimus.
Howard Gurney +4 more
openaire +3 more sources
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment [PDF]
, 2016 Background: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients experience relapses with a median ...
Caruso, Davide +4 more
core +2 more sources
Biochemical Pharmacology, 2015 Proteasome inhibitors have a 20 year history in cancer therapy. The first proteasome inhibitor, bortezomib (Velcade, PS-341), a break-through multiple myeloma treatment, moved rapidly through development from bench in 1994 to first approval in 2003. Bortezomib is a reversible boronic acid inhibitor of the chymotrypsin-like activity of the proteasome ...
Teicher, Beverly A. +1 more
openaire +2 more sources
SGLT2 Inhibitors and the Diabetic Kidney [PDF]
, 2016 Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing this complication; however, once DN is established, it is only possible to slow progression ...
Busetto, Luca +4 more
core +1 more source
Inhibitors of caeruloplasmin [PDF]
Biochemical Journal, 1967 1. A method is described by which substances inhibiting caeruloplasmin oxidase activity directly may be distinguished from those acting on stimulatory contaminant iron or on the product of enzyme action. 2. Many previously reported inhibitors, including saturated aliphatic carboxylates, hydrazines, 1,10-phenanthroline, borate and various psycho-active ...
Barbara E. Speyer, G. Curzon
openaire +3 more sources